The Significance of Endothelial Heterogeneity in Thrombosis and Hemostasis

ABSTRACT

The endothelium is recognized today as a functional and dynamic component of the body that plays an important part in health and disease. This article briefly reviews the role of endothelium in thrombosis and hemostasis. There is a paradigm shift from one that regards the endothelium as one single entity to the concept that the endothelium is heterogeneous. Thrombotic complications in many disorders show a predilection to specific locations, despite the fact that a hypercoagulable state affects the entire body. Likewise, bleeding is more commonly encountered in certain anatomical locations than in others. Recent observations of the heterogeneous distribution of coagulation and fibrinolytic factors in the endothelium and the adaptation of the endothelium to various stimuli may provide an explanation for the diverse phenotypes. Recognition of this changing paradigm is helpful to for the diagnosis and management of bleeding and thrombotic complications. It also helps in the understanding of the pathogenesis of many bleeding and thrombotic disorders, and in the development of new drug designs for site-specific therapy.

KEYWORDS

Endothelium - thrombosis - hemostasis - hemorrhage

REFERENCES

• 1 His W. Die Häute und Höhlen des Körpers. Basel, Switzerland; Schwighauser 1865
• 2 Rosenberg R D, Aird W C. Vascular-bed—specific hemostasis and hypercoagulable states.  N Engl J Med. 1999;  340(20) 1555-1564
• 3 Aird W C. Endothelial cell heterogeneity.  Crit Care Med. 2003;  31(4, suppl) S221-S230
• 4 Aird W C. Mechanisms of endothelial cell heterogeneity in health and disease.  Circ Res. 2006;  98(2) 159-162
• 5 Aird W C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms.  Circ Res. 2007;  100(2) 158-173
• 6 Aird W C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds.  Circ Res. 2007;  100(2) 174-190
• 7 Aird W C. Molecular heterogeneity of tumor endothelium.  Cell Tissue Res. 2009;  335(1) 271-281
• 8 Aird W C. Vascular bed-specific thrombosis.  J Thromb Haemost. 2007;  5(suppl 1) 283-291
• 9 Pries A R, Kuebler W M. Normal endothelium.  Handb Exp Pharmacol. 2006;  (176 Pt 1) 1-40
• 10 Bennett H S, Luft J H, Hampton J C. Morphological classifications of vertebrate blood capillaries.  Am J Physiol. 1959;  196(2) 381-390
• 11 Tse D, Stan R V. Morphological heterogeneity of endothelium.  Semin Thromb Hemost. 2010;  36(3) 236-245
• 12 Aird W C. Spatial and temporal dynamics of the endothelium.  J Thromb Haemost. 2005;  3(7) 1392-1406
• 13 Cushman M. Epidemiology and risk factors for venous thrombosis.  Semin Hematol. 2007;  44(2) 62-69
• 14 Stam J. Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;  352(17) 1791-1798
• 15 Ferro J M, Canhão P, Stam J, Bousser M G, Barinagarrementeria F. ISCVT Investigators . Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).  Stroke. 2004;  35(3) 664-670
• 16 Athale U H, Chan A K. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.  Thromb Res. 2003;  111(3) 125-131
• 17 Payne J H, Vora A J. Thrombosis and acute lymphoblastic leukaemia.  Br J Haematol. 2007;  138(4) 430-445
• 18 Caruso V, Iacoviello L, Di Castelnuovo A et al.. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.  Blood. 2006;  108(7) 2216-2222
• 19 Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati M B. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis.  J Thromb Haemost. 2007;  5(3) 621-623
• 20 Athale U H, Chan A K. Thrombosis in children with acute lymphoblastic leukemia. Part II Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy.  Thromb Res. 2003;  111(4–5) 199-212
• 21 Zakarija A, Kwaan H C. Adverse effects on hemostatic function of drugs used in hematologic malignancies.  Semin Thromb Hemost. 2007;  33(4) 355-364
• 22 Athale U H, Chan A K. Thrombosis in children with acute lymphoblastic leukemia. Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment.  Thromb Res. 2003;  111(6) 321-327
• 23 deVeber G, Andrew M, Adams C Canadian Pediatric Ischemic Stroke Study Group et al. Cerebral sinovenous thrombosis in children.  N Engl J Med. 2001;  345(6) 417-423
• 24 Coutinho J M, Ferro J M, Canhão P et al.. Cerebral venous and sinus thrombosis in women.  Stroke. 2009;  40(7) 2356-2361
• 25 Martinelli I, Taioli E, Palli D, Mannucci P M. Risk of cerebral vein thrombosis and oral contraceptives.  Lancet. 1998;  352(9124) 326
• 26 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.  N Engl J Med. 1998;  338(25) 1793-1797
• 27 Lanska D J, Kryscio R J. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis.  Stroke. 2000;  31(6) 1274-1282
• 28 Cantu C, Alonso E, Jara A et al.. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis.  Stroke. 2004;  35(8) 1790-1794
• 29 Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia in cerebral vein thrombosis.  Blood. 2003;  102(4) 1363-1366
• 30 Warkentin T E, Greinacher A. Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;  353(3) 314-315
• 31 Hillmen P, Lewis S M, Bessler M, Luzzatto L, Dacie J V. Natural history of paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 1995;  333(19) 1253-1258
• 32 Socié G, Mary J Y, de Gramont A French Society of Haematology et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors.  Lancet. 1996;  348(9027) 573-577
• 33 Ziakas P D, Poulou L S, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review.  Curr Vasc Pharmacol. 2008;  6(4) 347-353
• 34 Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.  Int J Hematol. 1997;  65(3) 285-291
• 35 Ziakas P D, Poulou L S, Rokas G I, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview.  J Thromb Haemost. 2007;  5(3) 642-645
• 36 De Stefano V, Fiorini A, Rossi E et al.. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.  J Thromb Haemost. 2007;  5(4) 708-714
• 37 Arya R, Shehata H A, Patel R K et al.. Internal jugular vein thrombosis after assisted conception therapy.  Br J Haematol. 2001;  115(1) 153-155
• 38 Baumann P, Diedrich K. Thromboembolic complications associated with reproductive endocrinologic procedures.  Hematol Oncol Clin North Am. 2000;  14(2) 431-443
• 39 Mancuso A, De Vivo A, Fanara G, Di Leo R, Toscano A. Upper body venous thrombosis associated with ovarian stimulation: case report and review of the literature.  Clin Exp Obstet Gynecol. 2005;  32(3) 149-154
• 40 Loret de Mola J R, Kiwi R, Austin C, Goldfarb J M. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome.  Fertil Steril. 2000;  73(6) 1253-1256
• 41 Stewart J A, Hamilton P J, Murdoch A P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques.  Hum Reprod. 1997;  12(10) 2167-2173
• 42 Chan W S, Ginsberg J S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART’ behind the clot.  J Thromb Haemost. 2006;  4(8) 1673-1677
• 43 Nelson S M. Prophylaxis of VTE in women—during assisted reproductive techniques.  Thromb Res. 2009;  123(suppl 3) S8-S15
• 44 Aune B, Oian P, Osterud B. Enhanced sensitivity of the extrinsic coagulation system during ovarian stimulation for in-vitro fertilization.  Hum Reprod. 1993;  8(9) 1349-1352
• 45 Lox C, Cañez M, DeLeon F, Dorsett J, Prien S. Hyperestrogenism induced by menotropins alone or in conjunction with luprolide acetate in in vitro fertilization cycles: the impact on hemostasis.  Fertil Steril. 1995;  63(3) 566-570
• 46 Bauersachs R M, Manolopoulos K, Hoppe I, Arin M J, Schleussner E. More on: the ‘ART’ behind the clot: solving the mystery.  J Thromb Haemost. 2007;  5(2) 438-439
• 47 Paterson J C, McLachlin J. Precipitating factors in venous thrombosis.  Surg Gynecol Obstet. 1954;  98(1) 96-102
• 48 Bergan J J, Schmid-Schönbein G W, Smith P D, Nicolaides A N, Boisseau M R, Eklof B. Chronic venous disease.  N Engl J Med. 2006;  355(5) 488-498
• 49 Hamer J D, Malone P C, Silver I A. The PO2 in venous valve pockets: its possible bearing on thrombogenesis.  Br J Surg. 1981;  68(3) 166-170
• 50 Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins.  J Clin Pathol. 1974;  27(7) 517-528
• 51 Kiladjian J J, Cervantes F, Leebeek F W et al.. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.  Blood. 2008;  111(10) 4922-4929
• 52 De Stefano V, Rossi E, Za T, Chiusolo P, Leone G. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.  Thromb Haemost. 2008;  99(6) 1121
• 53 Kralovics R, Passamonti F, Buser A S et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352(17) 1779-1790
• 54 Wasserman L R, Balcerzak S P, Berk P D et al.. Influence of therapy on causes of death in polycythemia vera.  Trans Assoc Am Physicians. 1981;  94 30-38
• 55 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  23(10) 2224-2232
• 56 Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera.  Acta Med Scand. 1962;  172 513-523
• 57 Landolfi R, Marchioli R, Kutti J European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators et al. Efficacy and safety of low-dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350(2) 114-124
• 58 Bellucci S, Michiels J J. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.  Semin Thromb Hemost. 2006;  32(4 Pt 2) 381-398
• 59 Cesar J M, de Miguel D, García Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100.  Am J Clin Pathol. 2005;  123(5) 772-777
• 60 Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.  Exp Hematol. 2005;  33(5) 523-530
• 61 Di Nisio M, Barbui T, Di Gennaro L European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Investigators et al. The haematocrit and platelet target in polycythemia vera.  Br J Haematol. 2007;  136(2) 249-259
• 62 Gangat N, Wolanskyj A P, Schwager S M, Hanson C A, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.  Cancer. 2009;  115(24) 5740-5745
• 63 Brækkan S K, Mathiesen E B, Njølstad I, Wilsgaard T, Hansen J B. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.  Haematologica. 2010;  95(2) 270-275
• 64 Bellucci S, Ignatova E, Jaillet N, Boffa M C. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.  Thromb Haemost. 1993;  70(5) 736-742
• 65 Yoder M C, Mead L E, Prater D et al.. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.  Blood. 2007;  109(5) 1801-1809
• 66 Patel R K, Lea N C, Heneghan M A et al.. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.  Gastroenterology. 2006;  130(7) 2031-2038
• 67 Sozer S, Fiel M I, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.  Blood. 2009;  113(21) 5246-5249
• 68 Hoekstra J, Leebeek F W, Plessier A European Network for Vascular Disorders of the Liver et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study.  J Hepatol. 2009;  51(4) 696-706
• 69 Ho V T, Linden E, Revta C, Richardson P G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.  Semin Thromb Hemost. 2007;  33(4) 373-388
• 70 DeLeve L D. Hepatic microvasculature in liver injury.  Semin Liver Dis. 2007;  27(4) 390-400
• 71 Tichelli A, Gratwohl A. Vascular endothelium as ‘novel’ target of graft-versus-host disease.  Best Pract Res Clin Haematol. 2008;  21(2) 139-148
• 72 Cooke K R, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2008;  14(1, suppl 1) 23-32
• 73 Richardson P G, Murakami C, Jin Z et al.. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.  Blood. 2002;  100(13) 4337-4343
• 74 Witlin A G, Sibai B M. Postpartum ovarian vein thrombosis after vaginal delivery: a report of 11 cases.  Obstet Gynecol. 1995;  85(5 Pt 1) 775-780
• 75 Heavrin B S, Wrenn K. Ovarian vein thrombosis: a rare cause of abdominal pain outside the peripartum period.  J Emerg Med. 2008;  34(1) 67-69
• 76 Cole M S, Minifee P K, Wolma F J. Coumarin necrosis—a review of the literature.  Surgery. 1988;  103(3) 271-277
• 77 Kipen C S. Gangrane of the breast—a complication of anticoagulant therapy. Report of two cases.  N Engl J Med. 1961;  265 638-640
• 78 Chan Y C, Valenti D, Mansfield A O, Stansby G. Warfarin induced skin necrosis.  Br J Surg. 2000;  87(3) 266-272
• 79 Becker C G. Oral anticoagulant therapy and skin necrosis: speculations on pathogenesis.  Adv Exp Med Biol. 1987;  214 217-222
• 80 Rose V L, Kwaan H C, Williamson K, Hoppensteadt D, Walenga J, Fareed J. Protein C antigen deficiency and warfarin necrosis.  Am J Clin Pathol. 1986;  86(5) 653-655
• 81 Vigano D'Angelo S, Comp P C, Esmon C T, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.  J Clin Invest. 1986;  77(2) 416-425
• 82 Kelton J G, Warkentin T E. Heparin-induced thrombocytopenia: a historical perspective.  Blood. 2008;  112(7) 2607-2616
• 83 Kwaan H C, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia.  Semin Thromb Hemost. 1999;  25(suppl 1) 23-27
• 84 Blank M, Shoenfeld Y, Tavor S et al.. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.  Int Immunol. 2002;  14(2) 121-129
• 85 Sadler J E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.  Blood. 2008;  112(1) 11-18
• 86 Kwaan H C, Boggio L N. The clinical spectrum of thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2005;  31(6) 673-680
• 87 Kwaan H C. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge.  Semin Thromb Hemost. 2005;  31(6) 615-624
• 88 Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2004;  30(5) 549-557
• 89 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombi of terminal arterioles and capillaries: an undescribed disease.  Proc NY Path Soc. 1924;  24 21-24
• 90 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307(23) 1432-1435
• 91 Mitra D, Jaffe E A, Weksler B, Hajjar K A, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood. 1997;  89(4) 1224-1234
• 92 Stefanescu R, Bassett D, Modarresi R, Santiago F, Fakruddin M, Laurence J. Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.  Blood. 2008;  112(2) 340-349
• 93 Kwaan H C. Endothelial cells are not all alike.  Blood. 2008;  112(2) 218
• 94 Ruiz-Torres M P, Casiraghi F, Galbusera M et al.. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.  Thromb Haemost. 2005;  93(3) 443-452
• 95 Zimmerhackl L B, Besbas N, Jungraithmayr T European Study Group for Haemolytic Uraemic Syndromes and Related Disorders et al. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome.  Semin Thromb Hemost. 2006;  32(2) 113-120
• 96 Karch H, Friedrich A W, Gerber A, Zimmerhackl L B, Schmidt M A, Bielaszewska M. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.  Semin Thromb Hemost. 2006;  32(2) 105-112
• 97 Obrig T G, Del Vecchio P J, Brown J E et al.. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.  Infect Immun. 1988;  56(9) 2373-2378
• 98 Obrig T G, Louise C B, Lingwood C A, Boyd B, Barley-Maloney L, Daniel T O. Endothelial heterogeneity in Shiga toxin receptors and responses.  J Biol Chem. 1993;  268(21) 15484-15488
• 99 Fujii J, Wood K, Matsuda F et al.. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein.  Infect Immun. 2008;  76(8) 3679-3689
• 100 Cervera R, Khamashta M A, Shoenfeld Y Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.  Ann Rheum Dis. 2009;  68(9) 1428-1432
• 101 Ruch J, McMahon B, Ramsey G, Kwaan H C. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab.  Am J Hematol. 2009;  84(2) 120-122
• 102 Francischetti I M, Seydel K B, Monteiro R Q. Blood coagulation, inflammation, and malaria.  Microcirculation. 2008;  15(2) 81-107
• 103 Michiels J J, Berneman Z N, Schroyens W, Van Vliet H H. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.  Platelets. 2004;  15(2) 67-84
• 104 Franchini M, Mannucci P M. Venous and arterial thrombosis: different sides of the same coin?.  Eur J Intern Med. 2008;  19(7) 476-481
• 105 Prandoni P, Bilora F, Marchiori A et al.. An association between atherosclerosis and venous thrombosis.  N Engl J Med. 2003;  348(15) 1435-1441
• 106 Prandoni P. Venous and arterial thrombosis: two aspects of the same disease?.  Eur J Intern Med. 2009;  20(6) 660-661
• 107 Ageno W, Prandoni P, Romualdi E et al.. The metabolic syndrome and the risk of venous thrombosis: a case-control study.  J Thromb Haemost. 2006;  4(9) 1914-1918
• 108 Ay C, Tengler T, Vormittag R et al.. Venous thromboembolism—a manifestation of the metabolic syndrome.  Haematologica. 2007;  92(3) 374-380
• 109 Hansson P O, Eriksson H, Welin L, Svärdsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the study of men born in 1913.”  Arch Intern Med. 1999;  159(16) 1886-1890
• 110 Goldhaber S Z, Grodstein F, Stampfer M J et al.. A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;  277(8) 642-645
• 111 Vayá A, Mira Y, Ferrando F et al.. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors.  Br J Haematol. 2002;  118(1) 255-259
• 112 Marcucci R, Liotta A A, Cellai A P et al.. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism.  Am J Med. 2003;  115(8) 601-605
• 113 Khawaja F J, Kullo I J. Novel markers of peripheral arterial disease.  Vasc Med. 2009;  14(4) 381-392
• 114 Ariesen M J, Claus S P, Rinkel G J, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review.  Stroke. 2003;  34(8) 2060-2065
• 115 Johansson L, Jansson J H, Stegmayr B, Nilsson T K, Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study.  Stroke. 2004;  35(4) 826-830
• 116 Naidech A M, Bernstein R A, Levasseur K et al.. Platelet activity and outcome after intracerebral hemorrhage.  Ann Neurol. 2009;  65(3) 352-356
• 117 Stein E, McMahon B, Kwaan H, Altman J K, Frankfurt O, Tallman M S. The coagulopathy of acute promyelocytic leukaemia revisited.  Best Pract Res Clin Haematol. 2009;  22(1) 153-163
• 118 Kwaan H C, Wang J, Boggio L N. Abnormalities in hemostasis in acute promyelocytic leukemia.  Hematol Oncol. 2002;  20(1) 33-41
• 119 Tallman M S, Hakimian D, Kwaan H C, Rickles F R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.  Leuk Lymphoma. 1993;  11(1–2) 27-36
• 120 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79(3) 543-553
• 121 Di Bona E, Avvisati G, Castaman G et al.. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.  Br J Haematol. 2000;  108(4) 689-695
• 122 de la Serna J, Montesinos P, Vellenga E et al.. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.  Blood. 2008;  111(7) 3395-3402
• 123 Tallman M S, Lefèbvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
• 124 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
• 125 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
• 126 Sanz M A, Montesinos P, Vellenga E et al.. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.  Blood. 2008;  112(8) 3130-3134
• 127 Athale U H, Chan A K. Hemorrhagic complications in pediatric hematologic malignancies.  Semin Thromb Hemost. 2007;  33(4) 408-415
• 128 Slats A M, Egeler R M, van der Does-van den Berg A et al.. Causes of death—other than progressive leukemia—in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience.  Leukemia. 2005;  19(4) 537-544
• 129 Goldhaber S Z, Bounameaux H. Thrombolytic therapy in pulmonary embolism.  Semin Vasc Med. 2001;  1(2) 213-220
• 130 Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.  Chest. 1997;  111(5) 1241-1245
• 131 Huynh T, Cox J L, Massel D FASTRAK II Network et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project.  Am Heart J. 2004;  148(1) 86-91
• 132 Micieli G, Marcheselli S, Tosi P A. Safety and efficacy of alteplase in the treatment of acute ischemic stroke.  Vasc Health Risk Manag. 2009;  5(1) 397-409
• 133 Ribo M, Montaner J, Molina C A et al.. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.  Stroke. 2004;  35(9) 2123-2127
• 134 Lansberg M G, Albers G W, Wijman C A. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.  Cerebrovasc Dis. 2007;  24(1) 1-10
• 135 Raanani P, Segal E, Levi I et al.. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA—a manifestation of the basic disease or the treatment.  Leuk Lymphoma. 2000;  37(5-6) 605-610
• 136 Vella A, Nippoldt T B, Morris III J C. Adrenal hemorrhage: a 25-year experience at the Mayo Clinic.  Mayo Clin Proc. 2001;  76(2) 161-168
• 137 Rao R H, Vagnucci A H, Amico J A. Bilateral massive adrenal hemorrhage: early recognition and treatment.  Ann Intern Med. 1989;  110(3) 227-235
• 138 Zissin R, Gayer G, Kots E, Ellis M, Bartal G, Griton I. Transcatheter arterial embolisation in anticoagulant-related haematoma—a current therapeutic option: a report of four patients and review of the literature.  Int J Clin Pract. 2007;  61(8) 1321-1327
• 139 Campbell N R, Hull R D, Brant R, Hogan D B, Pineo G F, Raskob G E. Aging and heparin-related bleeding.  Arch Intern Med. 1996;  156(8) 857-860
• 140 Astrup T, Sjolin K E. Thromboplastic and fibrinolytic activity of human synovial membrane and fibrous capsular tissue.  Proc Soc Exp Biol Med. 1958;  97(4) 852-853
• 141 Caughey D E, Highton T C. Components of the fibrinolytic system in synovial joints. Normal bovine compared with normal and abnormal human synovial joints.  Ann Rheum Dis. 1967;  26(4) 297-305
• 142 Hollestelle M J, Thinnes T, Crain K et al.. Tissue distribution of factor VIII gene expression in vivo—a closer look.  Thromb Haemost. 2001;  86(3) 855-861
• 143 Yamamoto K, de Waard V, Fearns C, Loskutoff D J. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo.  Blood. 1998;  92(8) 2791-2801
• 144 Rand J H, Badimon L, Gordon R E, Uson R R, Fuster V. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location.  Arteriosclerosis. 1987;  7(3) 287-291
• 145 Wu Q Y, Drouet L, Carrier J L et al.. Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease.  Arteriosclerosis. 1987;  7(1) 47-54
• 146 Bahnak B R, Wu Q Y, Coulombel L et al.. Expression of von Willebrand factor in porcine vessels: heterogeneity at the level of von Willebrand factor mRNA.  J Cell Physiol. 1989;  138(2) 305-310
• 147 Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer.  Cell Tissue Res. 2009;  335(1) 205-222
• 148 Ishii H, Salem H H, Bell C E, Laposata E A, Majerus P W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.  Blood. 1986;  67(2) 362-365
• 149 Lupu C, Westmuckett A D, Peer G et al.. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis.  Am J Pathol. 2005;  167(4) 1161-1172
• 150 Sawdey M S, Loskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.  J Clin Invest. 1991;  88(4) 1346-1353
• 151 Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.  J Clin Invest. 1996;  97(11) 2440-2451
• 152 Bidwell E. Fibrinolysins of human plasma; a comparison of fibrinolytic plasma from normal subjects and from cadaver blood with plasmin prepared by activation with chloroform.  Biochem J. 1953;  55(3) 497-506
• 153 Kwaan H C, McFadzean A J, Cook J. Plasma fibrinolytic activity in cirrhosis of the liver.  Lancet. 1956;  270(6908) 132-136
• 154 Kwaan H C, McFadzean A J, Cook J. On plasma fibrinolytic activity in cryptogenetic splenomegaly.  Scott Med J. 1957;  2(4) 137-150
• 155 Mackman N. On the trail of microparticles.  Circ Res. 2009;  104(8) 925-927
• 156 Morel O, Toti F, Hugel B et al.. Procoagulant microparticles: disrupting the vascular homeostasis equation?.  Arterioscler Thromb Vasc Biol. 2006;  26(12) 2594-2604
• 157 Morel O, Toti F, Bakouboula B, Grunebaum L, Freyssinet J M. Procoagulant microparticles: ‘criminal partners’ in atherothrombosis and deleterious cellular exchanges.  Pathophysiol Haemost Thromb. 2006;  35(1–2) 15-22
• 158 Burnier L, Fontana P, Kwak B R, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine.  Thromb Haemost. 2009;  101(3) 439-451
• 159 Furie B, Furie B C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation.  Trends Mol Med. 2004;  10(4) 171-178
• 160 Thomas G M, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.  J Exp Med. 2009;  206(9) 1913-1927
• 161 Carnemolla R SV, Shuvaev V V, Muzykantov V. Targeting antioxidant and anti-thrombotic biotherapeutics to endothelium.  Semin Thromb Hemost. 2010;  36(3) 332-342